NEW YORK (360Dx) – Laboratory Corporation of America announced today that it will acquire specialty contract research organization Chiltern for roughly $1.2 billion in cash.

According to LabCorp, Chiltern brings a strong presence among emerging-to-mid biopharma customers, as well as expertise in early-stage drug development, medical device development, and oncology. It also offers robust functional service provider (FSP) solutions and an endpoint suite of interactive response technology.